Drugs / HY6725
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07262281 | Feb 2026 → Mar 2027 expected | — | Newsoara Biopharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HY6725 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07262281 ↗ |
| Action | Inhibit | “simultaneously neutralize human TSLP and IL-33” NCT07262281 ↗ |
| Modality | Monoclonal antibody | “HY6725 is a novel, fully human monoclonal antibody engineered to simultaneously neutralize human TSLP and IL-33.” NCT07262281 ↗ |
| Route | Subcutaneous | “SAD part for subcutaneous dosing in 7 cohorts” NCT07262281 ↗ |
| Target | TSLP | “HY6725 is a novel, fully human monoclonal antibody engineered to simultaneously neutralize human TSLP and IL-33.” NCT07262281 ↗ |